Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S
Department of Radiation Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
Indian J Cancer. 2017 Jan-Mar;54(1):362-367. doi: 10.4103/ijc.IJC_157_17.
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The standard management has been maximum surgical resection followed by adjuvant radiotherapy with concurrent chemotherapy followed by adjuvant chemotherapy. Although the survival rate of patients with GBM has improved with recent advancements in treatment, the prognosis remains generally poor. The median survival rates are in the range of 9-12 months and 2-year survival rates are in the range of 8%-12%.
A single-institution retrospective review of 61 patients of GBM from 2012 to 2014. Data regarding patient factors, disease factors, and treatment factors were collected and survival has been calculated.
A total of 61 patients with GBM were analyzed. GBM is commonly seen in sixth decade of life. Male to female ratio is 2.6:1. The right side of the brain is commonly involved with right frontal lobe being the most common site. The median follow-up was 4.6 months. The median survival of our patients was 8 months. The 1-year and 2-year survival rates were 20% and 3.27%, respectively.
The overall survival and prognosis in patients with GBM remains poor despite of constant research and studies. Concurrent chemoradiotherapy followed by adjuvant chemotherapy with temozolomide should be used after maximal resection to improve the survival.
多形性胶质母细胞瘤（GBM）是成人中最常见且侵袭性最强的原发性脑肿瘤。标准治疗方法是最大程度的手术切除，随后进行同步放化疗的辅助放疗，接着进行辅助化疗。尽管随着近期治疗进展，GBM患者的生存率有所提高，但预后总体仍较差。中位生存期在9至12个月范围内，2年生存率在8%至12%范围内。
对2012年至2014年期间61例GBM患者进行单机构回顾性研究。收集了有关患者因素、疾病因素和治疗因素的数据，并计算了生存率。
共分析了61例GBM患者。GBM常见于60岁左右。男女比例为2.6:1。脑右侧常受累，右侧额叶是最常见部位。中位随访时间为4.6个月。我们患者的中位生存期为8个月。1年和2年生存率分别为20%和3.27%。
尽管不断进行研究，但GBM患者的总体生存和预后仍然较差。在最大程度切除后，应采用同步放化疗接着替莫唑胺辅助化疗以提高生存率。
